A sugar additive used in several foods could have helped spread a seriously dangerous superbug around the US, according to a 2018 study. ScienceAlert reports: The finger of blame is pointed squarely at the sugar trehalose, found in foods such as nutrition bars and chewing gum. If the findings are confirmed, it's a stark warning that even apparently harmless additives have the potential to cause health issues when introduced to our food supply. In this case, trehalose is being linked with the rise of two strains of the bacterium Clostridium difficile, capable of causing diarrhea, colitis, organ failure, and even death. The swift rise of the antibiotic-resistant bug has become a huge problem for hospitals in recent years, and the timing matches up with the arrival of trehalose. "In 2000, trehalose was approved as a food additive in the United States for a number of foods from sushi and vegetables to ice cream," said one of the researchers, Robert Britton from the Baylor College of Medicine in Texas, back in January 2018. "About three years later the reports of outbreaks with these lineages started to increase. Other factors may also contribute, but we think that trehalose is a key trigger." The C. difficile lineages Britton is referring to are RT027 and RT078. When the researchers analysed the genomes of these two strains, they found DNA sequences that enabled them to feed off low doses of trehalose sugar very efficiently. In fact, these particular bacteria need about 1,000 times less trehalose to live off than other varieties of C. difficile, thanks to their genetic make-up. [...] It's still not certain that trehalose has contributed to the rise of C. difficile, but the study results and the timing of its approval as an additive are pretty compelling. More research will now be needed to confirm the link. According to figures from the CDC, "C. difficile was responsible for half a million infections across the year and 29,000 deaths within the first 30 days of diagnosis," adds ScienceAlert. The findings were published in the journal Nature.

Read more of this story at Slashdot.

Slashdot reader sciencehabit quotes Science magazine: In his 1972 Nobel Prize acceptance speech, American biochemist Christian Anfinsen laid out a vision: One day it would be possible, he said, to predict the 3D structure of any protein merely from its sequence of amino acid building blocks. With hundreds of thousands of proteins in the human body alone, such an advance would have vast applications, offering insights into basic biology and revealing promising new drug targets. Now, after nearly 50 years, researchers have shown that artificial intelligence (AI)-driven software can churn out accurate protein structures by the thousands—an advance that realizes Anfinsen's dream and is Science's 2021 Breakthrough of the Year. Protein structures could once be determined only through painstaking lab analyses. But they can now be calculated, quickly, for tens of thousands of proteins, and for complexes of interacting proteins. "This is a sea change for structural biology," says Gaetano Montelione, a structural biologist at Rensselaer Polytechnic Institute. David Baker, a University of Washington, Seattle, computational biochemist who led one of the prediction projects, adds that with the bounty of readily available structures, "All areas of computational and molecular biology will be transformed."

Read more of this story at Slashdot.

fahrbot-bot shares a report from Phys.Org: A research team at the University of Wisconsin-Madison has identified a new way to convert ammonia to nitrogen gas through a process that could be a step toward ammonia replacing carbon-based fuels. The discovery of this technique, which uses a metal catalyst and releases -- rather than requires -- energy, was reported Nov. 8 in Nature Chemistry and has received a provisional patent from the Wisconsin Alumni Research Foundation. The scientists were excited to find that the addition of ammonia to a metal catalyst containing the platinum-like element ruthenium spontaneously produced nitrogen, which means that no added energy was required. Instead, this process can be harnessed to produce electricity, with protons and nitrogen gas as byproducts. In addition, the metal complex can be recycled through exposure to oxygen and used repeatedly, all a much cleaner process than using carbon-based fuels. "We figured out that, not only are we making nitrogen, we are making it under conditions that are completely unprecedented," says Berry, who is the Lester McNall Professor of Chemistry and focuses his research efforts on transition metal chemistry. "To be able to complete the ammonia-to-nitrogen reaction under ambient conditions -- and get energy -- is a pretty big deal." Ammonia has been burned as a fuel source for many years. During World War II, it was used in automobiles, and scientists today are considering ways to burn it in engines as a replacement for gasoline, particularly in the maritime industry. However, burning ammonia releases toxic nitrogen oxide gases. The new reaction avoids those toxic byproducts. If the reaction were housed in a fuel cell where ammonia and ruthenium react at an electrode surface, it could cleanly produce electricity without the need for a catalytic converter.

Read more of this story at Slashdot.

AltMachine shares a report from Phys.Org: Chinese scientists recently reported a de novo route for artificial starch synthesis from carbon dioxide (CO2) for the first time. Relevant results were published in Science on Sept. 24. The new route makes it possible to produce starch, a major component of grains, by industrial manufacturing instead of traditional agricultural planting and opens up a new technical route for synthesizing complex molecules from CO2. The artificial route can produce starch from CO2 with an efficiency 8.5-fold higher than starch biosynthesis in maize, suggesting a big step towards going beyond nature. It provides a new scientific basis for creating biological systems with unprecedented functions. "If the overall cost of the process can be reduced to a level economically comparable with agricultural planting in the future, it is expected to save more than 90% of cultivated land and freshwater resources," said MA Yanhe, corresponding author of the study. In addition, it would also help to avoid the negative environmental impact of using pesticides and fertilizers, improve human food security, facilitate a carbon-neutral bioeconomy, and eventually promote the formation of a sustainable bio-based society.

Read more of this story at Slashdot.

An anonymous reader quotes a report from Ars Technica: Engineers at Columbia University [...] figured out how to simultaneously 3D-print and cook layers of pureed chicken, according to a recent paper published in the journal npj Science of Food. [...] The scientists purchased raw chicken breast from a local convenience store and then pureed it in a food processor to get a smooth, uniform consistency. They removed any tendons and refrigerated the samples before repackaging them into 3D-printing syringe barrels to avoid clogging. The cooking apparatus used a high-powered diode laser, a set of mirror galvanometers (devices that detect electrical current by deflecting light beams), a fixture for custom 3D printing, laser shielding, and a removable tray on which to cook the 3D-printed chicken. "During initial laser cooking, our laser diode was mounted in the 3D-printed fixture, but as the experiments progressed, we transitioned to a setup where the laser was vertically mounted to the head of the extrusion mechanism," the authors wrote. "This setup allowed us to print and cook ingredients on the same machine." They also experimented with cooking the printed chicken after sealing it in plastic packaging. The results? The laser-cooked chicken retained twice as much moisture as conventionally cooked chicken, and it shrank half as much while still retaining similar flavors. But different types of lasers produced different results. The blue laser proved ideal for cooking the chicken internally, beneath the surface, while the infrared lasers were better at surface-level browning and broiling. As for the chicken in plastic packaging, the blue laser did achieve slight browning, but the near-infrared laser was more efficient at browning the chicken through the packaging. The team was even able to brown the surface of the packaged chicken in a pattern reminiscent of grill marks. "Millimeter-scale precision allows printing and cooking a burger that has a level of done-ness varying from rare to well-done in a lace, checkerboard, gradient, or other custom pattern," the authors wrote. "Heat from a laser can also cook and brown foods within a sealed package... [which] could significantly increase their shelf life by reducing their microbial contamination, and has great commercial applications for packaged to-go meals at the grocery store, for example." To make sure the 3D-printed chicken still appealed to the human palate, the team served samples of both 3D-printed laser cooked and conventionally cooked chicken to two taste testers. It's not a significant sample size, but both taste testers preferred the laser-cooked chicken over the conventionally cooked chicken, mostly because it was less dry and rubbery and had a more pleasing texture. One tester was even able to identify which sample was the laser-cooked chicken and did note a slight metallic taste from the laser heating.

Read more of this story at Slashdot.

Impossible Foods' latest meatless product is set to hit tables from Thursday: plant-based pork that claims to be tastier and healthier than the real deal. CNBC reports: The ground pork product will first be available in restaurants in the U.S., Hong Kong and Singapore, with further plans for retail expansion in those markets in the coming months. It marks the California-based company's third commercial launch after ground beef and chicken nuggets as it seeks to solidify its position in the growing plant-based protein space. Speaking in a first-on interview ahead of the launch, Impossible Foods' president Dennis Woodside told CNBC's "Squawk Box Asia" that the pork alternative could beat the real deal in both taste and nutritional value. "Pig typically isn't regarded as a healthy product, but here you have a substitute that tastes just as good but is actually better for you," he said. According to the company, the product -- which is made primarily from soy -- provides the same amount of protein as its traditional meat counterpart, but with no cholesterol, one-third less saturated fat, and far fewer calories. Meantime, in a recent blind taste test conducted by Impossible Foods, it found that the majority (54%) of Hong Kong consumers said they preferred the meatless pork product.

Read more of this story at Slashdot.

"A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing," reports Fierce Biotech: We don't like to throw the word "cure" around here. But Excision BioTherapeutics thinks the therapy could replace standard-of-care retroviral therapy, which keeps HIV from replicating but does not remove it from the body. That means patients stay on the treatment, which can cause serious side effects and affect quality of life. Now with the start of human testing, the real path to see if this new and lauded tech can accomplish this really begins. HIV integrates its genetic material into the genome of a host cell, meaning available therapies just can't remove it. A team of scientists at Temple University and the University of Nebraska Medical Center managed to remove the virus completely from mice during preclinical testing using a combination of CRISPR and antiretroviral therapy. They also found no adverse events that could be linked to the therapy in the study, published back in 2019... EBT-101 has since been tested in nonhuman primates, which showed it reached every tissue in the body where HIV reservoirs reside. Excision licensed the therapy from the universities with a goal of moving it into clinical trials. Now, the FDA is on board. The biotech plans to initiate a phase 1/2 clinical trial later this year, according to the statement. The technology used by Excision was licensed from the lab of famed CRISPR pioneer Jennifer Doudna. The company is also working on similar treatments for other viruses, including herpes and hepatitis B.

Read more of this story at Slashdot.

"Thanks to a breakthrough in RNA manipulation, crop scientists have developed new potato and rice varieties with higher yields and increased drought tolerance," reports UPI: By inserting a gene responsible for production of a protein called FTO, scientists produced bigger rice and potato plants with more expansive root systems. In experiments, the plants' longer roots improved their drought resistance. Test results — detailed Thursday in the journal Nature Biotechnology — showed the RNA-manipulated plants also improved their rate of photosynthesis, boost yields by as much as 50 percent... In the lab, the manipulated rice plants grew at three times their normal rate. In the field, the rice plants increased their mass by 50 percent. They also sprouted longer roots, increased their photosynthesis rate and produced larger yields. When they repeated the experiments with potato plants, the researchers got similar results, suggesting the new gene manipulation method could be used to bolster a variety of crops. The researchers hope this could help crops survive climate change, and even prevent forests from being cleared for food production, according to the article. And one of the study's co-authors adds "This really provides the possibility of engineering plants to potentially improve the ecosystem as global warming proceeds."

Read more of this story at Slashdot.

USA Today reports: Companies like Moderna and Pfizer's partner BioNTech, whose names are familiar from COVID-19 vaccines, are using mRNA to spur cancer patients' bodies to make vaccines that will — hopefully — prevent recurrences and treatments designed to fight off advanced tumors. If they prove effective, which won't be known for at least another year or two, they could be added to the arsenal of immune therapies designed to get the body to fight off its own tumors... Over the last decade, pharmaceutical companies around the world have been developing new ways to train the body's immune system to fight off tumors, particularly melanoma. They had learned how to remove a brake installed by tumors, unleashing the warriors of the immune system. Ten years ago, only about 5% of people with advanced melanoma survived for five years. Now, nearly half make it that long. Trials of mRNA cancer vaccines aim to boost that number even higher by adding soldiers to the fight... Once a tumor has been largely removed through surgery, a vaccine can help generate new immune soldiers known as T cells... A computer algorithm analyzes the mutations distinct to the cancer cells, looking for ones that trigger the production of T cells, said Melissa J. Moore, Moderna's chief scientific officer, of platform research. So far, she said, Moderna, working with partner Merck, has tested these personalized vaccines in about 100 patients. They aim eventually to make a personalized mRNA vaccine within about 45 days after the patient's cancer surgery, during their recovery... Mutated cancer cells have proteins on their surface that can be targeted by an mRNA vaccine. For a tumor that has, say, five common mutations, a patient could get a combination of five of these vaccines. On Friday, BioNTech announced it was launching a new trial for this approach, testing it in 120 melanoma patients Europe, the United Kingdom, Australia and the U.S. The new treatment, given in connection with an antibody from Regeneron, is aimed at four tumor-associated antigens. More than 90% of melanoma tumors contain at least one of the four. The U.S. federal government now lists 29 studies underway or that will be soon investigating mRNA cancer vaccines, according to the article. And Dr. Stephen Hahn, who had a career as an oncologist before running the Food and Drug Administration from 2019 until early this year, "said he's more optimistic this time because of how much researchers have learned about the role the immune system plays in cancer. 'That gives us an edge to maybe finally get to the place where we need to be.'"

Read more of this story at Slashdot.

Implantable miniaturized medical devices that wirelessly transmit data "are transforming healthcare and improving the quality of life for millions of people," writes Columbia University, noting the devices are "widely used to monitor and map biological signals, to support and enhance physiological functions, and to treat diseases." Long-time Slashdot reader sandbagger shares the university's newest announcement: These devices could be used to monitor physiological conditions, such as temperature, blood pressure, glucose, and respiration for both diagnostic and therapeutic procedures. To date, conventional implanted electronics have been highly volume-inefficient — they generally require multiple chips, packaging, wires, and external transducers, and batteries are often needed for energy storage... Researchers at Columbia Engineering report that they have built what they say is the world's smallest single-chip system, consuming a total volume of less than 0.1 mm cubed. The system is as small as a dust mite and visible only under a microscope... "We wanted to see how far we could push the limits on how small a functioning chip we could make," said the study's leader Ken Shepard, Lau Family professor of electrical engineering and professor of biomedical engineering. "This is a new idea of 'chip as system' — this is a chip that alone, with nothing else, is a complete functioning electronic system. This should be revolutionary for developing wireless, miniaturized implantable medical devices that can sense different things, be used in clinical applications, and eventually approved for human use...." The chip, which is the entire implantable/injectable mote with no additional packaging, was fabricated at the Taiwan Semiconductor Manufacturing Company with additional process modifications performed in the Columbia Nano Initiative cleanroom and the City University of New York Advanced Science Research Center (ASRC) Nanofabrication Facility. Shepard commented, "This is a nice example of 'more than Moore' technology—we introduced new materials onto standard complementary metal-oxide-semiconductor to provide new function. In this case, we added piezoelectric materials directly onto the integrated circuit to transducer acoustic energy to electrical energy...." The team's goal is to develop chips that can be injected into the body with a hypodermic needle and then communicate back out of the body using ultrasound, providing information about something they measure locally. The current devices measure body temperature, but there are many more possibilities the team is working on.

Read more of this story at Slashdot.

CNN recently reported on "a batch" of new studies published Wednesday — with one quantifying how much immunity improves after the second dose, and others showing how well coronavirus vaccines work against new variants of the virus: The first nationwide study of coronavirus vaccination, done in Israel, showed Pfizer/BioNtech's vaccine works far better after two doses. Two shots of the vaccine provided greater than 95% protection from infection, severe illness and death, Dr. Eric Haas of the Israel Ministry of Health and colleagues reported in the Lancet medical journal. "Two doses of BNT162b2 are highly effective across all age groups in preventing symptomatic and asymptomatic SARS-CoV-2 infections and COVID-19-related hospitalizations, severe disease, and death, including those caused by the B.1.1.7 SARS-CoV-2 variant," they wrote. The B.1.1.7 variant, first seen in Britain, has spread widely and is now the most common new variant seen in the US. It was also common in Israel when the study was done... "By 14 days after vaccination, protections conferred by a second dose [of the Pfizer vaccine] increased to 96.5% protection against infection, 98% against hospitalization, and 98.1% against death," the team wrote. But people who got only one dose of the vaccine were far less protected. One dose alone gave just 57.7% protection against infection, 75.7% against hospitalization, and 77% against death.... Separately, a team in the Gulf state of Qatar looked at the efficacy of Pfizer's vaccine in the population there when B.1.351 and B.1.1.7 were both circulating. They found reassuring results. "The estimated effectiveness of the vaccine against any documented infection with the B.1.1.7 variant was 89.5% at 14 or more days after the second dose. The effectiveness against any documented infection with the B.1.351 variant was 75%," the researchers wrote in a letter to the New England Journal of Medicine... Vaccine maker Moderna reported Wednesday that a booster shot delivering a half-dose of its current vaccine revs up the immune response against both B.1.351 and P.1. And a booster dose formulated specifically to match B.1.351 was even more effective, Moderna said in a statement... In another study, vaccine maker Novavax confirmed earlier findings that showed its vaccine protects against B.1.351.

Read more of this story at Slashdot.

An anonymous reader quotes a report from the BBC: The world's biggest jeweller, Pandora, says it will no longer sell mined diamonds and will switch to exclusively laboratory-made diamonds. Concerns about the environment and working practices in the mining industry have led to growing demand for alternatives to mined diamonds. Pandora's chief executive, Alexander Lacik, told the BBC the change was part of a broader sustainability drive. He said the firm was pursuing it because "it's the right thing to do." They are also cheaper: "We can essentially create the same outcome as nature has created, but at a very, very different price." Mr Lacik explains they can be made for as little as "a third of what it is for something that we've dug up from the ground." Pandora's lab-made diamonds are being made in Britain, and the UK is the first country where they will be sold. The new diamond jewelry will start at $350. [...] One problem with lab-made diamonds, though, is that they can take a lot of energy to produce. Between 50% and 60% of them come from China, where they are made in a process known as "high-pressure, high-temperature technology." The use of coal powered electricity is widespread. However in the United States, the biggest retail market for lab-grown diamonds, there is a greater focus on using renewable energy. The largest US producer, Diamond Foundry, says its process is "100% hydro-powered, meaning zero emissions." Both types are chemically and physically identical to mined diamonds.

Read more of this story at Slashdot.

Long-time Slashdot reader destinyland writes: The New York Times tells the story of Hungarian-born Dr. Kariko, whose father was a butcher and who growing up had never met a scientist — but knew they wanted to be one. Despite earning a Ph.D. at Hungary's University of Szeged and working as a postdoctoral fellow at its Biological Research Center, Kariko never found a permanent position after moving to the U.S., "instead clinging to the fringes of academia." Now 66 years old, Dr. Kariko is suddenly being hailed as "one of the heroes of Covid-19 vaccine development," after spending an entire career focused on mRNA, "convinced mRNA could be used to instruct cells to make their own medicines, including vaccines." From the article: For many years her career at the University of Pennsylvania was fragile. She migrated from lab to lab, relying on one senior scientist after another to take her in. She never made more than $60,000 a year... She needed grants to pursue ideas that seemed wild and fanciful. She did not get them, even as more mundane research was rewarded. "When your idea is against the conventional wisdom that makes sense to the star chamber, it is very hard to break out," said Dr. David Langer, a neurosurgeon who has worked with Dr. Kariko... Kariko's husband, Bela Francia, manager of an apartment complex, once calculated that her endless workdays meant she was earning about a dollar an hour. The Times also describes a formative experience in 1989 with cardiologist Elliot Barnathan: One fateful day, the two scientists hovered over a dot-matrix printer in a narrow room at the end of a long hall. A gamma counter, needed to track the radioactive molecule, was attached to a printer. It began to spew data. Their detector had found new proteins produced by cells that were never supposed to make them — suggesting that mRNA could be used to direct any cell to make any protein, at will. "I felt like a god," Dr. Kariko recalled. Yet Kariko was eventually left without a lab or funds for research, until a chance meeting at a photocopying machine led to a partnership with Dr. Drew Weissman of the University of Pennsylvania: "We both started writing grants," Dr. Weissman said. "We didn't get most of them. People were not interested in mRNA. The people who reviewed the grants said mRNA will not be a good therapeutic, so don't bother.'" Leading scientific journals rejected their work. When the research finally was published, in Immunity, it got little attention... "We talked to pharmaceutical companies and venture capitalists. No one cared," Dr. Weissman said. "We were screaming a lot, but no one would listen." Eventually, though, two biotech companies took notice of the work: Moderna, in the United States, and BioNTech, in Germany. Pfizer partnered with BioNTech, and the two now help fund Dr. Weissman's lab.

Read more of this story at Slashdot.

"Scientists have demonstrated the first human use of a wireless brain-computer interface, a potential breakthrough for people with paralysis," reports The Next Web (in a story shared by Slashdot reader Hmmmmmm): While traditional BCIs are tethered to users via cables, the new system — called BrainGate — replaces the cords with a small transmitter affixed atop a users' head. The unit then connects to an electrode array implanted in the brain's motor cortex. In a clinical trial, two participants with paralysis used the system to point, click, and type on a standard tablet computer. They both achieved similar typing speeds and point-and-click accuracy as those attained with wired systems. The researchers say it's the first time a device has transmitted the full spectrum of signals recorded by a sensor in the brain's motor cortex.

Read more of this story at Slashdot.

According to Reuters, Impossible Foods is preparing for a public listing which could value the U.S. plant-based burger maker at around $10 billion or more. From the report: This would be substantially more than the $4 billion the company was worth in a private funding round in 2020. It would highlight growing demand for plant-based meat products, driven by environmental and ethical concerns among consumers. Impossible Foods is exploring going public through an initial public offering (IPO) in the next 12 months or a merger with a so-called special purpose acquisition company (SPAC), the sources said. The Redwood City, California-based company has worked with a financial adviser to help manage discussions with SPACs after receiving offers at a lucrative valuation, the sources said. Going public through a SPAC could dilute existing Impossible Foods shareholders, however, by a greater extent than an IPO, the sources added. The sources, who requested because the discussions are private, cautioned that the deliberations are subject to market conditions and the company may opt to pursue another private fundraising round.

Read more of this story at Slashdot.

The NBA expects all arenas to be at full capacity next season, thanks to increased COVID-19 testing and more vaccines being administered. Another key aspect toward that effort is the NBA's new multiyear leaguewide partnership with Clear, a biometric screening company known for its expedited security process at hundreds of airports worldwide. ESPN reports: The partnership makes Clear's COVID-19 health screening technology available to all 30 teams in their NBA arenas, and it's expected to help facilitate more fans returning to games, though it's up to each team how to use the technology. Conversations for a leaguewide partnership began in early September. This is Clear's first leaguewide partnership with a professional sports league, but the company has been working with teams in MLS, MLB, NHL and the NFL. Clear first rolled out this program in a leaguewide format with the NHL's bubble season across two cities in Canada last year. As it pertains to attendance, fans can download the Clear app and upload an identifying document along with a selfie. To link their COVID-19 test results, fans log into their testing account through the app, and results will be linked to their health pass. Before entering the venue, fans can open the app, verify their identity with another selfie and then answer health survey questions. (There are also expected to be an unspecified number of Clear kiosks where fans receive a temperature check and scan their QR code.) Fans are issued a red or green notification depending on their COVID-related health information. A Clear spokesperson noted that the arenas only receive information about whether a fan has passed the requirements for access and not any private health information from the individual. They said that the Clear program is scalable, and could facilitate thousands of fans entering arenas.

Read more of this story at Slashdot.

"New vaccine trials hold great promise in the management of an East African strain of African swine fever, one of the most devastating diseases to afflict pigs," writes Cornell's Alliance for Science (a group who gives its mission as correcting misinformation and countering conspiracy theories slowing progress on issues including synthetic biology and agricultural innovations). Slashdot reader wooloohoo shares their report: Scientists at the International Livestock Research Institute (ILRI) are employing CRISPR Cas9 editing and synthetic biology to modify the ASFV genome in order to attenuate the virus for a live vaccine to help reduce deaths from African swine fever. Up to 10 vaccine candidates have been lined up for tests, in a project that commenced in 2016... African swine fever is present in 26 African countries, Steinaa observed, as well as in parts of Asia and Europe. An effective vaccine could be a breakthrough for pig farmers across the globe... With a 100 percent fatality rate and a highly contagious nature, African swine fever poses a potent threat to the global pig farming industry. The rapid spread of the disease portends social and economic disruptions wherever it strikes.

Read more of this story at Slashdot.

Slashdot reader wooloohoo shares a new article from Cornell's Alliance for Science, a group who gives its mission as correcting misinformation and countering conspiracy theories slowing progress on issues including synthetic biology and agricultural innovations: There are two types of chickens: the broilers that we eat and the layers that produce the eggs. The layers don't have enough meat to make them useful for human consumption and since only hens can lay eggs, that leaves the male layers useless. As a result, billions of newly hatched male layer chicks are killed each year. Now the Israeli ag-tech startup eggXYt has found a way to humanely address this dilemma through the use of CRISPR — the gene editing technique that allows scientists to make targeted, specific genetic tweaks... By using CRISPR, eggXYt's scientists can edit the genes of chickens to make them lay sex-detectable eggs... The global egg industry saves the costs and the ethical conundrum of killing half of its product and billions of additional eggs are added to the global market to help meet growing demand.

Read more of this story at Slashdot.

U.S. plant-based protein company Beyond Meat has signed global supply deals with fast food firms McDonald's and Yum! Brands, which includes KFC, Pizza Hut, Taco Bell and others. AgFunderNews reports: The three-year strategic agreement with McDonald's will see Beyond Meat become the 'preferred supplier' of patties for the fast food chain's new McPlant plant-based burger. Under their separate strategic partnership, Beyond Meat and Yum! Brands will co-develop a range of exclusive plant-based protein menu items for the latter's KFC, Pizza Hut, and Taco Bell chains. Bruce Friedrich, executive director of the Good Food Institute, said in comments sent to AFN that the two deals represent "the clearest sign yet that the future of meat will be plant-based." "The world's largest restaurant chains are placing plant-based meat directly on the plates of millions of customers around the world," he said. "With more restaurants and revenue than any other food chains on the planet, McDonald's and Yum! Brands will bring plant-based meat onto the mainstream menus of millions of people. When these restaurant chains move, the entire food industry takes notice."

Read more of this story at Slashdot.

A new research study at the University of Missouri is using CRISPR gene-editing technology to produce mosquitoes that are unable to replicate Zika virus and therefore cannot infect a human through biting. Slashdot reader wooloohoo shared an announcement from Cornell's Alliance for Science: Alexander Franz, an associate professor in the MU College of Veterinary Medicine, collaborated with researchers at Colorado State University... Their work was recently published in the journal Viruses. Franz added that the genetic modification is inheritable, so future generations of the altered mosquitoes would be resistant to Zika virus as well... "[W]e are simply trying to expand the toolbox and provide a solution by genetically modifying the mosquitoes to become Zika-resistant while keeping them alive at the same time." Franz' research is designed to help prevent another outbreak of Zika virus disease from occurring while also addressing concerns that have some have raised about reducing populations of mosquitoes, which are a food source for some animals... The study was funded by the National Institutes of Health.

Read more of this story at Slashdot.